Commercial Sanofi posts upbeat sales as R&D pressure builds BioPharma DiveA string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over.CommercialRead full story pharminent April 23, 2026 (Last updated: April 23, 2026) BioPharma Dive A string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. CommercialRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: BBOT shakes up leadership as RAS competitors get more visibilityNext: Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs Related Stories Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026 Commercial Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval pharminent June 26, 2026
